Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authorscopusidAli Zarrabi / 23483174100en_US
dc.authorwosidAli Zarrabi / U-2602-2019
dc.contributor.authorMostafavi, E.
dc.contributor.authorZarepour, A.
dc.contributor.authorBarabadi, H.
dc.contributor.authorZarrabi, A.
dc.contributor.authorTruong, L.B.
dc.contributor.authorMedina-Cruz, D.
dc.date.accessioned2022-04-06T05:37:13Z
dc.date.available2022-04-06T05:37:13Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractThe American Cancer Society estimated around 61,090 new cases of leukemia were diagnosed, and around 23,660 people died from this disease in the United States alone in 2021. Due to its burden on society, there is an unmet need to explore innovative approaches to overcome leukemia. Among different strategies that have been explored, nanotechnology appears to be a promising and effective approach for therapeutics. Specifically, biogenic silver and gold nanoparticles (NPs) have attracted significant attention for their antineoplastic activity toward leukemia cancer cells due to their unique physicochemical properties. Indeed, these nanostructures have emerged as useful approaches in anti-leukemic applications, either as carriers to enhance drug bioavailability and its targeted delivery to a specific organ or as a novel therapeutic agent. This review explores recent advances in green synthesized nanomaterials and their potential use against leukemia, especially focusing on silver (Ag) and gold (Au) nanostructures. In detail, we have reviewed various eco-friendly methods of bio-synthesized NPs, their analytical properties, and toxicity effects against leukemic models. This overview confirms the satisfactory potency of biogenic NPs toward leukemic cells and desirable safety profiles against human native cells, which opens a promising door toward commercializing these types of nontherapeutic agents if challenges involve clinical validations, reproducibility, and scalability could be resolved. © 2022en_US
dc.identifier.citationMostafavi, E., Zarepour, A., Barabadi, H., Zarrabi, A., Truong, L. B., & Medina-Cruz, D. (2022). Antineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnostic. Biotechnology Reports, 34, e00714.en_US
dc.identifier.doi10.1016/j.btre.2022.e00714en_US
dc.identifier.issn2215-017Xen_US
dc.identifier.scopus2-s2.0-85126315312en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.btre.2022.e00714
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2597
dc.identifier.volume34en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofBiotechnology Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiosynthesisen_US
dc.subjectGold NPssen_US
dc.subjectLeukemiaen_US
dc.subjectMetallic Nanomaterialsen_US
dc.subjectSilver NPsen_US
dc.subjectTherapeuticen_US
dc.titleAntineoplastic activity of biogenic silver and gold nanoparticles to combat leukemia: Beginning a new era in cancer theragnosticen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
66.pdf
Boyut:
21.85 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Biyomedikal Mühendisliği Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu